[go: up one dir, main page]

MX2023001912A - Tratamiento de la sepsis con moduladores de pcsk9 y ldlr. - Google Patents

Tratamiento de la sepsis con moduladores de pcsk9 y ldlr.

Info

Publication number
MX2023001912A
MX2023001912A MX2023001912A MX2023001912A MX2023001912A MX 2023001912 A MX2023001912 A MX 2023001912A MX 2023001912 A MX2023001912 A MX 2023001912A MX 2023001912 A MX2023001912 A MX 2023001912A MX 2023001912 A MX2023001912 A MX 2023001912A
Authority
MX
Mexico
Prior art keywords
sepsis
ldlr
pcsk9
methods
modulators
Prior art date
Application number
MX2023001912A
Other languages
English (en)
Inventor
Amy Damask
Garen Manvelian
Aris Baras
Julie Horowitz
Charles Paulding
Manuel Allen Revez Ferreira
Luca Andrea Lotta
Michael Cantor
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2023001912A publication Critical patent/MX2023001912A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Telephone Function (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción proporciona métodos para el tratamiento de sujetos que tienen sepsis, SIRS, choque séptico y/o MODS, métodos para la identificación de sujetos que tienen un mayor riesgo de desarrollar sepsis, SIRS, choque séptico y/o MODS, y métodos para la detección de polipéptidos variantes y moléculas de ácidos nucleicos variantes de receptor de lipoproteínas de baja densidad (LDLR) y/o proproteína convertasa subtilisina/kexina tipo 9 (PCSK9).
MX2023001912A 2020-08-25 2021-08-25 Tratamiento de la sepsis con moduladores de pcsk9 y ldlr. MX2023001912A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063069789P 2020-08-25 2020-08-25
PCT/US2021/047502 WO2022046873A1 (en) 2020-08-25 2021-08-25 Treatment of sepsis with pcsk9 and ldlr modulators

Publications (1)

Publication Number Publication Date
MX2023001912A true MX2023001912A (es) 2023-07-10

Family

ID=77775030

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001912A MX2023001912A (es) 2020-08-25 2021-08-25 Tratamiento de la sepsis con moduladores de pcsk9 y ldlr.

Country Status (10)

Country Link
US (1) US20220064652A1 (es)
EP (1) EP4204563A1 (es)
JP (1) JP2023539742A (es)
KR (1) KR20230057410A (es)
CN (1) CN116171161A (es)
AU (1) AU2021335200A1 (es)
CA (1) CA3191030A1 (es)
IL (1) IL300439A (es)
MX (1) MX2023001912A (es)
WO (1) WO2022046873A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119716057B (zh) * 2024-12-10 2025-07-15 中国人民解放军总医院 Pcsk6在诊断脓毒症中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX352457B (es) * 2012-05-17 2017-11-24 Cyon Therapeutics Inc Metodos y usos para inhibidores de proproteina convertasa subtilisina kexina 9 (pcsk9).
BR112016007255A2 (pt) * 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
JP7046381B2 (ja) * 2016-09-20 2022-04-04 オーフス ウニベルシテット リポタンパク質代謝障害の治療のための化合物
WO2020010186A1 (en) * 2018-07-06 2020-01-09 Derek Klarin Pcsk9 variants
CN113166101A (zh) * 2018-11-27 2021-07-23 诺华股份有限公司 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状五聚体化合物

Also Published As

Publication number Publication date
IL300439A (en) 2023-04-01
EP4204563A1 (en) 2023-07-05
US20220064652A1 (en) 2022-03-03
AU2021335200A1 (en) 2023-04-27
CN116171161A (zh) 2023-05-26
KR20230057410A (ko) 2023-04-28
WO2022046873A1 (en) 2022-03-03
AU2021335200A9 (en) 2024-10-03
JP2023539742A (ja) 2023-09-19
CA3191030A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
auf dem Keller et al. Systems-level analysis of proteolytic events in increased vascular permeability and complement activation in skin inflammation
Aung et al. 3D traction stresses activate protease-dependent invasion of cancer cells
Nakada et al. Roles of membrane type 1 matrix metalloproteinase and tissue inhibitor of metalloproteinases 2 in invasion and dissemination of human malignant glioma
MX2023001912A (es) Tratamiento de la sepsis con moduladores de pcsk9 y ldlr.
Ricci et al. Substrate-zymography: a still worthwhile method for gelatinases analysis in biological samples
BR9908567A (pt) Processos de detecção de ácido nucléico zimogênico e moléculas relacionadas e kits
Liu et al. Carbonic anhydrases III and IV autoantibodies in rheumatoid arthritis, systemic lupus erythematosus, diabetes, hypertensive renal disease, and heart failure
Morihiro et al. Fatty acid binding protein 7 as a marker of glioma stem cells
IL130036A0 (en) Survivin a protein that inhibits cellular apoptosis and its modulation
WO2014144080A3 (en) Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
Di Carlo Matrix metalloproteinase-2 and-9 in the sera and in the urine of human oncocytoma and renal cell carcinoma
Wan et al. Exosome-related multi-pass transmembrane protein TSAP6 is a target of rhomboid protease RHBDD1-induced proteolysis
RU2007141930A (ru) Способ in vitro идентификации соединений для лечения рака
Brinet et al. An improved capillary electrophoresis method for in vitro monitoring of the challenging early steps of Aβ1–42 peptide oligomerization: Application to anti‐Alzheimer's drug discovery
ATE291736T1 (de) Verfahren zur bestimmung des zustandes von keratin enthaltenden materialien
ATE219581T1 (de) Methode zum nachweis übertragbarer spongiformer enzephalopathien
ATE274053T1 (de) Methode zur identifizierung von verbindungen die mit rac proteine kinase interagieren
MX2024003301A (es) Biomarcadores de base inmunitaria sérica para su uso en la terapia de la ela.
Niida‐Kawaguchi et al. Soluble iron accumulation induces microglial glutamate release in the spinal cord of sporadic amyotrophic lateral sclerosis
Tamamoto et al. Serum amyloid A promotes invasion of feline mammary carcinoma cells
Recio et al. Protein changes in stored ultra-high-temperature-treated milks studied by capillary electrophoresis and high-performance liquid chromatography
ATE349010T1 (de) Standard für immunhistochemie, immunzytologie und molekulare zytogenetika
MX2021011015A (es) Tratamiento de la hiperglucemia con inhibidores del miembro 5 de la familia 39 de los transportadores de solutos (slc39a5).
Troeberg et al. Measurement of matrix metalloproteinase activities in the medium of cultured synoviocytes using zymography
FR2849205B1 (fr) Procede d'amplification de la detection de la prpsc et utilisation d'un ligand adjuvant macrocyclique pour une telle amplification